Dublin, Ireland--(Marketwire - March 18, 2008) -

                           AGI Therapeutics PLC

                         Notification of Results
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, will be announcing its preliminary results for the year ended 31 December 2007 on Thursday, 3 April 2008.

An analyst briefing will be held at 09.30am on 3 April 2008 at the offices of Piper Jaffray, One South Place, London EC2M 2RB.

Contact Information:

AGI Therapeutics plc.                       Tel: +353 1 449 3254
David Kelly, Chief Financial Officer

Financial Dynamics - UK                     Tel: +44 (0) 20 7269 7182
Deborah Scott/Lara Mott

Financial Dynamics - Ireland                Tel: +353 1 663 3607
Aisling Garvey

Piper Jaffray Limited                       Tel: +44 (0) 20 3142 8700
Neil Mackison
Will Carnwath

Davy                                        Tel: +353 (1) 614 8761
John Frain

Notes to Editors:

About AGI Therapeutics plc

AGI is a speciality pharmaceutical company which is focused on the development and commercialisation of differentiated drug products for gastrointestinal (GI) diseases and disorders. AGI's common shares are listed on the Alternative Investment Market of the London Stock Exchange (AIM) and on the Irish Enterprise Exchange of the Irish Stock Market (IEX) as AGI.

The Company has a portfolio of product candidates derived from its Known Molecular Entity (KME) approach to drug re-profiling and development. The Company's lead product candidate, Rezular, is an orally administered triple-action intestinal regulator, a first-in-class mechanism for the treatment of Diarrhoea predominant Irritable Bowel Syndrome, (IBS-D). Rezular is currently in Phase III clinical trials.

KME is a re-profiling methodology used by the Company to identify existing therapeutic drugs which typically have been marketed for a number of years, have established safety profiles and can be developed for new clinical indications or with improved profiles in their existing clinical indications. In this way, the Company seeks to reduce the risk, time and cost of new product development as compared to the development of new chemical entities.

AGI is developing a range of product candidates to treat a variety of prevalent GI diseases and disorders, including irritable bowel syndrome (IBS), dyspepsia, gastroparesis, ulcerative colitis, gastro-esophageal reflux disease (GERD) and diarrhoea-related conditions such as chemotherapy-induced diarrhoea (CID). The Company is targeting areas of the GI therapeutic drug products market for its product candidates where there are currently unmet medical needs or where the effectiveness of existing drug therapies can be further improved.

The Company has five active clinical stage product candidates which are either isomers or new drug delivery formulations of existing approved drugs, and which have established safety and tolerability profiles in their currently approved clinical indications.

For further information please see www.agitherapeutics.com

                      This information is provided by RNS
            The company news service from the London Stock Exchange